Haley Mabrey, MD
Family Medicine · Cullman, ALNPI 1598284739
Payments from drug & device makers
Across 292 payments — averaging $18.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$660
- Novo Nordisk$541
- Pfizer$530
- AbbVie$399
- AstraZeneca$334
- GSK$284
- plus $3K from 32 others
What the payments were for
- Food & beverage$5,08094%
- Education$3516%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 22 | $660 |
| Novo Nordisk | 27 | $541 |
| Pfizer | 34 | $530 |
| AbbVie | 23 | $399 |
| AstraZeneca | 19 | $334 |
| GSK | 18 | $284 |
| Abbott | 11 | $246 |
| Lilly USA, LLC | 11 | $221 |
| Bayer | 9 | $178 |
| Axsome Therapeutics, Inc. | 8 | $175 |
| Otsuka America Pharmaceutical, Inc. | 8 | $157 |
| Boehringer Ingelheim | 11 | $156 |
| E.r. Squibb & Sons, L.L.C. | 9 | $151 |
| Exact Sciences | 7 | $144 |
| Amgen(2 entities) | 9 | $139 |
| Merck | 8 | $134 |
| Johnson & Johnson | 8 | $111 |
| Dexcom, Inc. | 6 | $106 |
| Harmony Biosciences LLC | 3 | $105 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $79 |
| Sunovion Pharmaceuticals Inc. | 8 | $70 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $68 |
| Jazz Pharmaceuticals Inc. | 2 | $51 |
| Novartis | 3 | $51 |
| Idorsia Pharmaceuticals US Inc | 3 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Sanofi-aventis U.S. LLC | 2 | $35 |
| Mylan Specialty L.p. | 2 | $33 |
| Sanofi | 1 | $28 |
| Endogastric Solutions, Inc | 1 | $25 |
| Seqirus USA Inc | 1 | $24 |
| Medtronic | 1 | $22 |
| Boston Scientific | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Sumitomo Pharma America, Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$5,431 in reported general payments places this provider in the 80th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 118 | $113,237 |
| EliquisApixaban | 119 | $83,773 |
| JardianceEmpagliflozin | 93 | $80,965 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 58 | $40,785 |
| XareltoRivaroxaban | 33 | $40,374 |
| JanuviaSitagliptin Phosphate | 38 | $33,764 |
| FarxigaDapagliflozin Propanediol | 26 | $27,557 |
| MounjaroTirzepatide | 15 | $18,304 |
| MyrbetriqMirabegron | 31 | $17,197 |
| LinzessLinaclotide | 22 | $14,658 |
| EntrestoSacubitril/Valsartan | 11 | $13,465 |
| Spiriva RespimatTiotropium Bromide | 21 | $10,659 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $7,970 |
| PremarinEstrogens, Conjugated | 17 | $6,456 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 57 | $6,436 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $541 | $113,237118 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat | $156 | $97,177126 claims |
| PfizerEliquis, Premarin, Dilantin | $530 | $92,971148 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Shingrix | $284 | $54,060101 claims |
| Johnson & JohnsonXarelto | $111 | $40,37433 claims |
| MerckJanuvia | $134 | $33,76438 claims |
| AstraZenecaFarxiga | $334 | $27,55726 claims |
| Lilly USA, LLCMounjaro | $221 | $18,30415 claims |
| Astellas Pharma US IncMyrbetriq | $660 | $17,19731 claims |
| AbbVieLinzess | $399 | $14,65822 claims |
| NovartisEntresto | $51 | $13,46511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Cullman
- Randall QuinnCullman$5.4M
- Ben BostickCullman$1.5M
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.